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Abstract
Background: The two-stage liver resection combining in situ liver transection with portal vein ligation, also referred
to as ALPPS (Associating Liver Partition and Portal vein ligation for Staged hepatectomy), has been described as a
promising method to increase the resectability of liver tumors. However, one of the most important issues
regarding the safety of this procedure is the optimal timing of the second stage at the point of sufficient
hypertrophy of the future liver remnant. The recently developed liver maximum function capacity test (LiMAx) can
be applied to monitor the liver function postoperatively and hence could be a useful tool for decision-making
regarding the timing of the second stage of ALPPS.
Case presentation: A 73-year-old female patient presented with metachronous colorectal liver metastasis
comprising the complete right liver lobe as well as segment IV. Due to an insufficient future liver remnant (19.3 %;
segments II and III of the liver) and a low future liver remnant:body weight ratio (0.28 %) the decision was made to
perform an ALPPS-procedure in order to avoid development of postoperative small-for-size syndrome. Despite a
formally sufficient increase of the FLR to 30.8 % within 7 days after the first step of ALPPS, the liver function was
seen to only slowly increase as expressed by a LiMAx value of 245 μg/h/kg (baseline of 282 μg/h/kg prior to
surgery). By means of the LiMAx test, sufficient increase of liver function eventually was detected by postoperative
day 11 (LiMAx value of 371 μg/h/kg; FLR 35.2 %) so that the second step of ALPPS (completion of hepatectomy)
was performed with no signs of liver failure during further clinical course.
Conclusion: Performing ALPPS we have observed a significant difference between the increase in future liver
remnant volume and function applying the LiMAx test. The latter tool thus might proof valuable for application in
two-stage liver resection to avoid postoperative small-for-size syndrome.
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Background
The recently developed strategy to perform a two-stage
liver resection combining in situ liver transection with
portal vein ligation, also known as the ALPPS-procedure
(Associating Liver Partition and Portal vein ligation for
Staged hepatectomy), has been described as a promising
method to increase the resectability of marginally resect-
able or locally unresectable liver tumors [1]. Since the
introduction of ALPPS, several groups worldwide have
adopted this new technique mainly to enlarge the pool
of patients with resectable colorectal liver metastases [2].
However, since the introduction of ALPPS the safety of
this procedure regarding morbidity and mortality is dis-
cussed controversially [3]. One of the advantages of the
ALPPS-procedure is the rapid and sufficient hypertrophy
of the future liver remnant (FLR) induced by the first
step of the operation [4, 5], therefore the right timing of
the second step is vital for the success of this approach.
The reference standard in the assessment of the FLR is a
combination of CT-volumetry and blood tests including
Quick value, cholinesterase (CHE), international normal-
ized ratio (INR) and Bilirubin [6]. However, in the ma-
jority of cases the final quality of the FLR in terms of
function remains pretty uncertain.
The likewise recently developed liver maximum func-
tion capacity test (LiMAx) [7] is based on the hepatocyte-
specific metabolism of the 13C-labelled substrate methace-
tin by the cytochrome P450 1A2 enzyme, which is ubiqui-
tously active throughout the liver. After i.v. injection, the
13C-methacetin is instantly metabolized into acetamino-
phen and 13CO2, which is pulmonarily exhaled. Hence,
the administration of 13C-methacetin leads to a significant
alteration of the normal 13CO2:
12CO2 ratio (Pee Dee Bel-
emnite standard 1.1237 %) [8] in the expired breath. This
alteration is determined by a suitable device called Fast
Liver Investigation Package (FLIP) which is connected to
the patient. Based on the 13CO2:
12CO2 ratio and the body
weight of the patient, the cytochrome P450 1A2 activity is
determined and expressed as the so-called LiMAx value
with the units μg/kg/h (μg methacetin/kg body weight/
hour). The analysis of the 13CO2:
12CO2 ratio is performed
over a period of 20 to 60 min. For normal liver function, a
LiMAx value more than 315 μg/kg/h is required. In
healthy volunteers, the normal range was found to be 425
± 67 μg/kg/h (range: 311–575 μg/kg/h) [9, 10].
Performing ALPPS, the precise assessment of the FLR
function seems to be more important than its volume
alone to determine the optimal time of hepatectomy to
avoid postoperative small-for-size syndrome [11]. The
described liver function determined by the LiMAx test
thus has the potential to help to define the right timing
of the second step of the ALPPS-procedure. Here we re-
port our experience with the LiMAx test in a patient
who recently underwent the ALPPS-procedure.
Case presentation
A 73-year old woman presented in our outpatient clinic
with metachronous colorectal liver metastasis. Previously
a right hemicolectomy had been performed for a pT3, N0,
M0 tumor. The CT-scan showed a large, colorectal
metastasis-typical lesion comprising the complete right
liver lobe as well as segment IV. Preoperative staging CT-
scan showed no extrahepatic tumor manifestations. The
patient expressed a strong wish for surgical therapy and
refused any neoadjuvant chemotherapy. Consequently, the
indication for liver resection was set and planned as an ex-
tended right hepatectomy (resection of segments IV-VIII).
However, conventional liver resection was considered as
too hazardous as the FLR was found to be only 19.3 % of
the total liver volume (325 cm3 and 1687 cm3, respect-
ively), which was below the volume cut-off value for safe
resections (>20 % of total liver volume) [12]. The
FLR:body weight (BW) ratio (FLR/BW) was only 0.28 %.
Furthermore, liver maximum function capacity deter-
mined by the LiMAx test was only 282 μg/h/kg, which is
reported to be associated with a significantly increased
morbidity and mortality after major liver resection
(>315 μg/h/kg required) [7]. In contrast, conventional la-
boratory values showed to be sufficient for a major liver
resection including Quick value (88 %), CHE (6.59 kU/l)
and Bilirubin (5 μmol/l) [13, 14]. In conclusion, due to the
low FLR volume, the low FLR/BW ratio and the low
LiMAx value, it was decided to apply the ALPPS-
procedure in order to induce hypertrophy of segments II
and III prior to hepatectomy. ALPPS was preferred to
conventional portal vein occlusion due to the known more
rapid hypertrophy of the FLR and thus the expectation to
lower the risk of tumor progression in this patient who re-
fused preoperative chemotherapy [4, 5].
The operation was started by careful exploration of the
abdominal cavity to rule out any extrahepatic manifesta-
tions followed by examination of the liver by palpation and
ultrasound to confirm the known lesion and to finally
evaluate operability. Then ALPPS was performed as previ-
ously reported [15]. In brief, the hepatoduodenal ligament
was dissected to isolate the right hepatic artery, portal vein
and bile duct. Then the right hepatic vein was isolated.
After transection of the right portal vein, the hepatic paren-
chyma was dissected between segments II/III and segment
IV. Small hepatic veins draining from the right liver into
the vena cava likewise were transected. The right liver lobe
was then wrapped in a silicone matting to prevent adhe-
sions while waiting for hypertrophy of the FLR. The patient
required 3 transfusions of packed red blood cells (pRBC)
intraoperatively and received 2 packages of fresh frozen
plasma (FFP) within the first 12 h postoperatively. Overall,
she showed an uneventful postoperative recovery after the
first step of the ALPPS-procedure. Nevertheless, due to the
advanced age of the patient, development of postoperative
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oedema with mild pulmonary restriction, high levels of liver
enzymes (see below) in conjunction with lack of experience
with this type of surgical approach, the patient was moni-
tored at the intensive care unit (ICU) for 7 days.
A CT-based volumetry on postoperative day (POD) 7
showed an increase of FLR volume to 519 cm3 represent-
ing approx. 30.8 % of the total liver volume with a FLR/
BW ratio of 0.45 (Fig. 1). However, the LiMAx test re-
vealed a functional capacity of still only 245 μg/h/kg.
Therefore the second step of the ALPPS-procedure was
delayed waiting for further hypertrophy and functional
uptake of the FLR. At this time the conventional liver
function values such as Quick value and Bilirubin already
recovered well but still did not reach their baseline. AST
and ALT levels were primarily significantly elevated to
2705 U/I and 2187 U/I on the first POD, respectively, but
constantly dropped to 46 U/I and 229 U/I on POD 7. The
courses of these laboratory values are depicted in Fig. 2.
A further CT-volumetry conducted on POD 11 showed
a FLR volume of 594 cm3 (approx. 35.2 % of the total liver
volume; FLR/BW ratio of 0.52) resulting in a volume in-
crease of about 82.8 % following step 1 of ALPPS. At this
time also a recovery of liver function as monitored
amongst others by the LiMAx test was observed. The lat-
ter now was found to be 371 μg/h/kg indicating sufficient
growth and function of the FLR (Fig. 3). Thus, the second
step of ALPPS was realized on POD 12. The mobilization
of the liver was performed without any difficulties. The sil-
icon matting covering the liver was removed; right hepatic
artery, right hepatic bile duct and right hepatic vein were
dissected. There was no major intraoperative complication
and no units of pRBC or FFP had to be transfused and the
patient could be discharged from ICU on POD 2.
Following the second step of ALPPS, the Quick value
again significantly dropped and Bilirubin rised on POD 1,
but recovered rapidly thereafter. Notably, on POD 3 the
bilirubin was higher than 50 μmol/l and the Quick value
below 50 % indicating a high risk for post hepatectomy
liver failure [6]. Nonetheless, after completion of ALPPS
the patient showed a stable liver function throughout the
entire postoperative course. AST and ALT levels were only
slightly elevated (Fig. 2). Unfortunately though, the patient
developed a peripheral bile leak. Applying endoscopic
sphincterotomy and biliary stenting the bile leak was suc-
cessfully treated and dissolved within a few days. The ab-
dominal drainages thus could be removed close by.
Eventually, the patient continually recovered from these
procedures and could be discharged on POD 30 after
completion of ALPPS.
Due to the above mentioned oncological diagnosis an
adjuvant chemotherapy with FOLFOX was recommended
by the interdisciplinary tumor board. The last oncological
staging was performed 12 month after ALPPS with no
signs of tumor recurrence.
Discussion
Mortality after the second step of the ALPPS-procedure
mainly is related to liver failure, therefore insufficient FLR
is one of the major challenges of ALPPS. The widely ac-
cepted cut-off values to perform the second step are FLR >
30 % (FLR/BW> 0.5 %) or > 40 % (FLR/BW> 0.8 %) de-
pending on the parenchymal quality of the liver [12]. The
lately published recommendations from the first Inter-
national ALPPS Expert Meeting in Hamburg, Germany,
states that the first CT-scan should be performed 8 days
after step one of the procedure [11] since the FLR growth
reaches a plateau after day 7 [16]. Furthermore, if there are
any signs of liver failure, step 2 should be delayed even
when sufficient FLR volume has been reached. The reliabil-
ity of function tests such as the Indocyanine Green (ICG)
test, the (99 m) Tc-mebrofenin hepatobiliary scintigraphy
(HBS) with SPECT-CT or the LiMAx test have not been
studied sufficiently, yet, in the setting of ALPPS. Therefore,
the degree of hypertrophy achieved after step 1 remains the
main criteria for decision-making about the timing of the
second step of the procedure, even though the correlation
between volumetric and functional increase of the FLR after
ALPPS is still a matter of debate.
We here demonstrate our preliminary experience with
the LiMAx test in combination with the conventional CT-
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Fig. 1 Pre- and postoperative CT-scan of the liver. a Preoperative CT-scan depicting the tumor lesion within the right liver lobe (marked pink)
and the resulting future liver remnant (FLR; marked purple). b CT-volumetry 7 days after the first step of ALPPS already resulted in a significant
increase of the FLR. The extended right liver lobe (wrapped in a silicone matting) meanwhile showed signs of necrosis following ligation of the
right portal vein. c CT-volumetry 11 days after the first step of ALPPS showed further growth of the FLR (marked red). POD = postoperative day
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volumetry of the liver to assess liver regeneration in the
case of an ALPPS-procedure. We were able to show a sub-
stantial difference between the increases in FLR volume
and function applying the LiMAx test (Fig. 3). When we
performed the first evaluation of FLR function and growth
7 days after the first stage of the resection, the FLR volume
had increased from 19.3 to 30.8 % indicating sufficient
growth to undergo the next step of the operation as the
cut-off value for safe resection was reached [12]. However,
the FLR function quantified by the LiMAx test was only
245 μg/h/kg, which is reported to be associated with high
morbidity and mortality after major resection [7]. Only four
days later, the FLR function had sufficiently increased to
371 μg/h/kg and the next step of the resection could be
performed safely. Therefore, we can report the same experi-
ence as Cieslak et al. using the (99 m) Tc-mebrofenin HBS
with SPECT-CT to measure liver function early after the
first stage of ALPPS that the volume of the FLR might over-
estimate its function [17]. Hence, there is a considerable
risk to induce postoperative small-for-size syndrome when
decision-making regarding the second stage of the ALPPS-







































Fig. 2 Postoperative course of AST, Bilirubin and Quick value. Diagram depicting the courses of AST, Bilirubin and Quick value following the first
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Fig. 3 Postoperative course of FLR, LiMAx value and Quick value. Diagram depicting the courses of FLR, LiMAx value and Quick value following
the first step of the ALPPS-procedure, respectively. POD = postoperative day
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Lately Malinowski et al. published their experience
with the LiMAx test for liver resection following portal
vein embolization (PVE) which at least partly has the
same physiological background to induce liver hyper-
trophy as the ALPPS-procedure. They showed that the
LiMAx value did not change rapidly after PVE, and be-
tween PVE and hepatectomy there was also only an in-
significant increase in the LiMAx value (on average from
360 to 401 μg/kg/h) showing a slow and homogeneous
remodeling process after the intervention [18]. Thus, in
conjunction with our present case, this again might
demonstrate the advantage of ALPPS over PVE regard-
ing a more rapid growth in liver volume and function,
and is in line with the conclusions drawn by others [19].
However, since the LiMAx test represents a global liver
function test just like the ICG test, there are also some
limitations. In contrast to imaging-based liver function
testing, global liver function tests have the disadvantage
that regional dysfunction or heterogeneous distribution of
liver function cannot be displayed. Especially in the case
of ALPPS it is assumed that liver function after the first
step of the procedure is no longer distributed equally over
the whole liver and therefore the prediction of postopera-
tive liver function remains challenging. The imaging based
liver function tests such as the (99 m) Tc-mebrofenin HBS
has the potential advantage that liver function can be dis-
played separately for the right and left lobe or as in the
case of ALPPS for the FLR as recently shown [17]. On the
other hand, current imaging based liver function tests are
not available for routine clinical use and are much more
cost and time intensive as compared to the LiMAx test
which is comparable easy to use and could be installed
ubiquitously much more readily.
Conclusion
LiMAx is a simple liver function test enabling monitor-
ing of FLR function in patients undergoing the ALPPS-
procedure. LiMAx thus has the potential to be a useful
tool in defining the optimal timing of the second stage
of ALPPS (Fig. 4) and hence might contribute substan-
tially to the improvement of the procedure-related mor-


























Fig. 4 Algorithm summarizing the recommendations for performance of ALPPS. Diagram summarizing the suggestions of the first International
ALPPS Expert Meeting in Hamburg [11] modified by possible implementation of the LiMAx test
Oldhafer et al. Patient Safety in Surgery  (2016) 10:16 Page 5 of 6
Abbreviations
ALPPS, Associating Liver Partition and Portal vein ligation for Staged hepatectomy;
CHE, cholinesterase; FFP, fresh frozen plasma; FLIP, Fast Liver Investigation
Package; FLR, future liver remnant; FLR/BW ratio, future liver remnant/body weight
ratio; HBS, hepatobiliary scintigraphy; ICG, Indocyanine Green; ICU, intensive care
unit; INR, international normalized ratio; LiMAx, liver maximum function capacity
test; POD, postoperative day; pRBC, packed red blood cells; PVE, portal vein
embolization.
Authors’ contributions
FO collected the data, reviewed the literature, performed the follow-up, and
wrote the main manuscript. He assisted during surgery. KIR performed the
CT-volumetry and supplied Fig. 1. She critically reviewed the manuscript. KT,
MK, WR and SC made critical suggestions for data interpretation and manu-
script improvement. They were involved in the postoperative treatment of
the patient on the ICU and surgical ward. MJ assisted during surgery. He was
involved in data acquisition and critically reviewed the manuscript. JK made
critical suggestions for data interpretation and gave final approval of the
manuscript. HB performed the surgery. He was involved in acquisition of
data, data interpretation and improvement of the manuscript. FWRV col-
lected the data, made substantial contributions to the conception and de-
sign of the study and made critical suggestions for data interpretation. He
helped writing the manuscript. He assisted during surgery. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Consent was obtained from the patient to publish this case as a report.
Ethics approval and consent to participate
Not applicable.
Author details
1Regenerative Medicine & Experimental Surgery (ReMediES); Department of
General, Visceral and Transplant Surgery, Hannover Medical School,
Carl-Neuberg-Str. 1, 30625 Hannover, Germany. 2Department of Diagnostic
and Interventional Radiology, Hannover Medical School, Hannover, Germany.
Received: 8 March 2016 Accepted: 17 May 2016
References
1. de Santibanes E, Clavien PA. Playing play-Doh to prevent postoperative liver
failure: the “ALPPS” approach. Ann Surg. 2012;255(3):415–7.
2. Hernandez-Alejandro R, Bertens KA, Pineda-Solis K, Croome KP. Can we
improve the morbidity and mortality associated with the associating liver
partition with portal vein ligation for staged hepatectomy (ALPPS)
procedure in the management of colorectal liver metastases? Surgery. 2015;
157(2):194–201.
3. Schadde E, Schnitzbauer AA, Tschuor C, Raptis DA, Bechstein WO, Clavien
PA. Systematic review and meta-analysis of feasibility, safety, and efficacy of
a novel procedure: associating liver partition and portal vein ligation for
staged hepatectomy. Ann Surg Oncol. 2015;22(9):3109–20.
4. Schnitzbauer AA, Lang SA, Goessmann H, Nadalin S, Baumgart J, Farkas SA,
et al. Right portal vein ligation combined with in situ splitting induces rapid
left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic
resection in small-for-size settings. Ann Surg. 2012;255(3):405–14.
5. Knoefel WT, Gabor I, Rehders A, Alexander A, Krausch M, Schulte Am Esch J, et
al. In situ liver transection with portal vein ligation for rapid growth of the
future liver remnant in two-stage liver resection. Br J Surg. 2013;100(3):388–94.
6. Paugam-Burtz C, Janny S, Delefosse D, Dahmani S, Dondero F, Mantz J, et
al. Prospective validation of the “fifty-fifty” criteria as an early and accurate
predictor of death after liver resection in intensive care unit patients. Ann
Surg. 2009;249(1):124–8.
7. Stockmann M, Lock JF, Malinowski M, Niehues SM, Seehofer D, Neuhaus P.
The LiMAx test: a new liver function test for predicting postoperative
outcome in liver surgery. HPB. 2010;12(2):139–46.
8. Schoeller DA, Schneider JF, Solomons NW, Watkins JB, Klein PD. Clinical
diagnosis with the stable isotope 13C in CO2 breath tests: methodology
and fundamental considerations. J Lab Clin Med. 1977;90(3):412–21.
9. Bednarsch J, Jara M, Lock JF, Malinowski M, Pratschke J, Stockmann M.
Noninvasive diagnosis of chemotherapy induced liver injury by LiMAx test–
two case reports and a review of the literature. BMC Res Notes. 2015;8:99.
10. Muller SA, Tarantino I, Corazza M, Pianka F, Fornaro J, Beutner U, et al. A
rapid and accurate new bedside test to assess maximal liver function: a
case report. Patient Saf Surgery. 2013;7:11.
11. Oldhafer KJ, Stavrou GA, van Gulik TM, core g. ALPPS-Where Do We Stand,
Where Do We Go?: Eight Recommendations From the First International
Expert Meeting. Annals of surgery. 2016;263(5):839–41.
12. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving
resectability of hepatic colorectal metastases: expert consensus statement.
Ann Surg Oncol. 2006;13(10):1271–80.
13. Donadon M, Costa G, Cimino M, Procopio F, Fabbro DD, Palmisano A, et al.
Safe hepatectomy selection criteria for hepatocellular carcinoma patients: a
validation of 336 consecutive hepatectomies. The BILCHE score. World J
Surg. 2015;39(1):237–43.
14. Donadon M, Cimino M, Procopio F, Morenghi E, Montorsi M, Torzilli G.
Potential role of cholinesterases to predict short-term outcome after hepatic
resection for hepatocellular carcinoma. Updat Surg. 2013;65(1):11–8.
15. Oldhafer F, Ringe KI, Timrott K, Kleine M, Ramackers W, Cammann S, et al.
Intraoperative conversion to ALPPS in a case of intrahepatic
cholangiocarcinoma. Case Rep Surg. 2015;2015:273641.
16. Truant S, Scatton O, Dokmak S, Regimbeau JM, Lucidi V, Laurent A, et al.
Associating liver partition and portal vein ligation for staged hepatectomy
(ALPPS): impact of the inter-stages course on morbi-mortality and
implications for management. Eur J Surg Oncol. 2015;41(5):674–82.
17. Cieslak KP, Olthof PB, van Lienden KP, Besselink MG, Busch OR, van Gulik
TM, et al. Assessment of liver function using (99 m)Tc-mebrofenin
hepatobiliary scintigraphy in ALPPS (Associating Liver Partition and Portal
Vein Ligation for Staged Hepatectomy). Case Rep Gastroenterol.
2015;9(3):353–60.
18. Malinowski M, Lock JF, Seehofer D, Gebauer B, Schulz A, Demirel L, et al.
Preliminary study on liver function changes after trisectionectomy with
versus without prior portal vein embolization. Surgery today. 2015.
[Epub ahead of print]
19. Schadde E, Ardiles V, Slankamenac K, Tschuor C, Sergeant G, Amacker N, et al.
ALPPS offers a better chance of complete resection in patients with primarily
unresectable liver tumors compared with conventional-staged hepatectomies:
results of a multicenter analysis. World J Surg. 2014;38(6):1510–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Oldhafer et al. Patient Safety in Surgery  (2016) 10:16 Page 6 of 6
